ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference

Rhea-AI Summary

ImmunoGen Inc. (Nasdaq: IMGN) announced participation in a fireside chat at the H.C. Wainwright Virtual Global Life Sciences Conference, scheduled for March 9, 2021, at 7:00 a.m. ET. Chief Financial Officer Susan Altschuller and Chief Medical Officer Anna Berkenblit will represent the company. The presentation will be available on-demand and can be accessed via the Investors and Media section of the company's website. ImmunoGen is focused on developing next-generation antibody-drug conjugates aimed at improving cancer treatment outcomes and enhancing patient quality of life.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming H.C. Wainwright Virtual Global Life Sciences Conference. The presentation will be available on-demand on March 9, 2021 at 7:00 a.m. ET.

A webcast of the presentation will be accessible through the Investors and Media section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005776/en/

FAQ

When is ImmunoGen's presentation at the H.C. Wainwright Virtual Global Life Sciences Conference?

ImmunoGen's presentation is scheduled for March 9, 2021, at 7:00 a.m. ET.

Who from ImmunoGen will participate in the conference?

Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in the conference.

How can I access the presentation by ImmunoGen?

The presentation can be accessed through the Investors and Media section of ImmunoGen's website.

What is the focus of ImmunoGen's drug development?

ImmunoGen is focused on developing next-generation antibody-drug conjugates to improve cancer treatment outcomes.